General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Underwriters in Veracyte’s Upsized Public Offering

February 8, 2021
A capital markets team represents the underwriters in the genomic diagnostics company’s offering.

Veracyte, Inc. has announced the pricing of an underwritten public offering of 7,432,433 shares of its common stock at a public offering price of US$74 per share. The gross proceeds to the Company from this offering, before deducting underwriting discounts and commissions and offering expenses payable by Veracyte, are expected to be approximately US$550 million. The public offering was upsized from the previously announced size of US$400 million in shares of common stock. All of the shares are being offered by the Company. In addition, the Company granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,114,864 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP advised the underwriters in the transaction with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Denis Griffin and Briana Goncalves.